Funder: National Institutes of Health

Due Dates: June 20, 2025 (New, Renewal/Resubmission/Revision) | September 7, 2025 (AIDS) | October 9, 2025 (New, Renewal/Resubmission/Revision) | January 7, 2026 (AIDS) | March 13, 2026 (New, Renewal/Resubmission/Revision) | May 7, 2026 (AIDS)

Funding Amounts: R61 phase: up to $500,000 direct costs (2 years); R33 phase: no budget cap (up to 3 years, actual needs); total project period up to 5 years.

Summary: Supports exploratory/developmental clinical neuroscience research to understand neurobiological mechanisms underlying substance use disorders using basic experimental studies with humans (BESH).

Key Information: Applicants must propose a phased R61/R33 project with clear, quantitative milestones; only basic experimental studies with humans (BESH) that meet the NIH clinical trial definition are eligible.